Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

阿格列汀 耐受性 医学 药代动力学 加药 药理学 药效学 二肽基肽酶-4抑制剂 安慰剂 尿 队列 内科学 曲线下面积 胃肠病学 二肽基肽酶-4 内分泌学 不利影响 2型糖尿病 糖尿病 替代医学 病理
作者
Ronald J. Christopher,Paul S. Covington,Michael Davenport,Penny Fleck,Qais Mekki,Elisabeth R. Wann,Aziz Karim
出处
期刊:Clinical Therapeutics [Elsevier]
卷期号:30 (3): 513-527 被引量:118
标识
DOI:10.1016/j.clinthera.2008.03.005
摘要

Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes.This study was conducted to characterize the pharmacokinetics, pharmacodynamics, and tolerability of single oral doses of alogliptin in healthy male subjects.This was a randomized, double-blind, placebo-controlled study in which healthy, nonobese male subjects between the ages of 18 and 55 years were assigned to 1 of 6 cohorts: alogliptin 25, 50, 100, 200, 400, or 800 mg. One subject in each cohort received placebo. An ascending-dose strategy was used, in which each cohort received its assigned dose only after review of the safety data from the previous cohort. Blood and urine were collected over 72 hours after dosing for pharmacokinetic analysis and determination of plasma DPP-4 inhibition and active glucagon-like peptide -1(GLP-1) concentrations.Thirty-six subjects (66 per cohort) were enrolled and completed the study (29/36 [81% ] white; mean age, 26.6 years; mean weight, 76.0 kg). Alogliptin was rapidly absorbed (median T(max), 1-2 hours) and eliminated slowly (mean t(1/2), 12.4-21.4 hours), primarily via urinary excretion (mean fraction of drug excreted in urine from 0 to 72 hours after dosing, 60%-71%). C(max) and AUC(0-infinity) increased dose proportionally over the range from 25 to 100 mg. The metabolites M-I (N-demethylated) and M-II (N-acetylated) accounted for <2% and <6%, respectively, of alogliptin concentrations in plasma and urine. Across alogliptin doses, mean peak DPP-4 inhibition ranged from 93% to 99%, and mean inhibition at 24 hours after dosing ranged from 74% to 97%. Exposure to active GLP-1 was 2- to 4-fold greater for all alogliptin doses compared with placebo; no dose response was apparent. Hypoglycemia (asymptomatic) was reported in 5 subjects (11 receiving alogliptin 50 mg, 2 receiving alogliptin 200 mg, 1 receiving alogliptin 400 mg, 1 receiving placebo). Other adverse events were reported in 1 subject each: dizziness (alogliptin 100 mg), syncope (alogliptin 200 mg), constipation (alogliptin 200 mg), viral infection (alogliptin 400 mg), hot flush (placebo), and nausea (placebo).In these healthy male subjects, alogliptin at single doses up to 800 mg inhibited plasma DPP-4 activity, increased active GLP-1, and was generally well tolerated, with no dose-limiting toxicity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
wang完成签到,获得积分10
1秒前
漂亮幻莲完成签到,获得积分10
1秒前
yoyo完成签到,获得积分10
2秒前
weddcf发布了新的文献求助10
2秒前
地火丢发布了新的文献求助10
2秒前
2秒前
abu关闭了abu文献求助
3秒前
3秒前
3秒前
领导范儿应助蛀牙联盟采纳,获得10
3秒前
漂亮幻莲发布了新的文献求助10
5秒前
斯文败类应助这个真不懂采纳,获得10
5秒前
5秒前
5秒前
在水一方应助jxf采纳,获得10
5秒前
充电宝应助肥鱼不会飞采纳,获得10
6秒前
6秒前
6秒前
JW完成签到,获得积分10
7秒前
黄剑兴发布了新的文献求助10
7秒前
7秒前
8秒前
我是老大应助奋斗的珍采纳,获得10
8秒前
孤独语薇发布了新的文献求助10
9秒前
10秒前
laohu2发布了新的文献求助10
10秒前
Shirley应助carbonhan采纳,获得10
10秒前
好旺完成签到,获得积分10
11秒前
睡睡白白完成签到,获得积分10
11秒前
hoongyan完成签到 ,获得积分10
11秒前
科研通AI2S应助Yara.H采纳,获得10
12秒前
12秒前
12秒前
魔幻友菱发布了新的文献求助10
12秒前
Mannose完成签到,获得积分10
13秒前
13秒前
怒吼的狮子完成签到,获得积分10
13秒前
黄剑兴完成签到,获得积分10
13秒前
13秒前
高分求助中
Evolution 10000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3147773
求助须知:如何正确求助?哪些是违规求助? 2798855
关于积分的说明 7831859
捐赠科研通 2455728
什么是DOI,文献DOI怎么找? 1306927
科研通“疑难数据库(出版商)”最低求助积分说明 627945
版权声明 601587